Public Event Detail
Bank of America Securities Remains a Buy on Crispr Therapeutics AG (CRSP)
Public historical observation from the Merrowstone archive. This page shows event-level context only. Accepted assertions, evidence lineage, and relationship intelligence remain part of the premium research layer.
Historical observations only. No forecasts, recommendations, buy/sell ratings, or portfolio advice.
2026-04-09METAMeta PlatformsAlpha Vantage Newsearnings
Event summary
Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Crispr Therapeutics AG (CRSP) with an $86.00 price target. This positive sentiment is supported by other analysts like H.C. Wainwright's Mitchell Kapoor, despite a recent Hold rating from TipRanks – OpenAI. The company reported $864 thousand in quarterly revenue and a $130.61 million GAAP net loss, and corporate insider sentiment is positive due to increased insider buying.
Attached public signals
Observed outcomes
7d returnPending
30d returnPending
90d returnPending
Relative 90d returnPending